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Key Points
•Methods that use an
MSKCC single 10-color
tube or EuroFlow two
8-color tubes provide
similar sensitivity in the
detection of MRD in
multiple myeloma.
In patients withmultiplemyeloma, obtaining posttreatmentminimal residual disease (MRD)
negativity is associated with longer progression-free survival and overall survival. Here, we
compared thediagnostic performanceof a single 10-color tubewith that of aEuroFlow8-color
2-tubepanel forMRD testing. Bonemarrow samples from41multiplemyelomapatientswere
tested in parallel using the 2 approaches. Compared with the sum of the cells from the
EuroFlow two 8-color tubes, the Memorial Sloan Kettering Cancer Center (MSKCC) single 10-
color tube had a slight reduction in total cell number with a mean ratio of 0.85 (range, 0.57-
1.46; P , .05), likely attributable to permeabilization of the cells. Percent of plasma cells
showed a high degree of concordance (r2 5 0.97) as did normal plasma cells (r2 5 0.96),
consistent with no selective plasma cell loss. Importantly, concordant measurement of
residual disease burden was seen with abnormal plasma cells (r2 5 0.97). The overall
concordance between the 2 tests was 98%. In 1 case, there was a discrepancy near the limit
of detection of both tests in favor of the slightly greater theoretical sensitivity of the
EuroFlow 8-color 2-tube panel (analytical sensitivity limit of MSKCC single 10-color tube: 6
cells in 1 million with at least 3 million cell acquisitions; EuroFlow 8-color 2-tube panel: 2
cells in 1 million with the recommended 10 million cell acquisitions).
Introduction
Minimal residual disease (MRD) negativity is associated with longer progression-free and overall survival
in multiple myeloma.1-7 Flow cytometry offers rapid, comparatively inexpensive MRD monitoring with
a proven sensitivity of 2 3 1026.8-10 The EuroFlow Consortium proposed an MRD test (including
10 specific antigens) that uses two 8-color tubes: a surface only tube and a surface/cytoplasmic tube.9
Although these methods are clearly effective, the inevitable drawback is increased costs resulting from
multiple antibody duplication and labor, which may pose barriers for wide clinical adoption of the test
outside dedicated centers and for applicability to patients treated outside major clinical trials. For example, in
the United States, reimbursement is not provided for the increased cost and effort of implementing this
resource-intensive method. Nonetheless, the updated 2016 International MyelomaWorking Group (IMWG)
clinical response criteria call for EuroFlow or an equivalent test to determine response to deep treatment.11
To reduce additional costs and labor burden for the laboratories, we investigated whether a streamlined
approach of combining surface and cytoplasmic staining in a single 10-color tube previously proposed
by the EuroFlow Consortium12 could offer similar test performance. Comparison of this approach with
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the EuroFlow 8-color 2-tube panel was performed in a series of
41 routinely obtained myeloma follow-up clinical samples.
Methods
Patients and samples for comparing MSKCC single
10-color tube with EuroFlow two 8-color tubes
All patients were treated at Memorial Sloan Kettering Cancer Center
(MSKCC) formultiplemyeloma (age, sex, and clinical status of the patients
according to IMWG criteria11 before MRDmeasurement are summarized
in Table 1). Per institutional standards, the studywas approved by the local
institutional reviewboard, and the studywasperformed in accordancewith
theDeclaration ofHelsinki. As part of a routine clinical care follow-up, 4mL
of bone marrow aspirate (first bone marrow aspiration pull) was obtained.
The samples were mixed, counted, assessed for viability and, to simulate
a real-life setting, split evenly (2 mL each) between the MSKCC single
10-color tube and the EuroFlow two 8-color tubes for evaluation. Twenty
million cells or the entire volume of the sample was used for each arm.
Processing, staining, and sample acquisition by the 2 methods was
performed in parallel within 24 hours of collection.
Evaluation procedure for comparison testing
Technical details and validation of both methods have been reported
elsewhere.10,13 Briefly, the MSKCC 10-color single-tube MRDmethod
uses EuroFlow bulk lysis followed by surface antibody staining, which
consists of a surface antibody cocktail of CD117PC5.5 (104D2D1),
CD19PC7 (J3-119), CD138APC (B-A38), and CD81PacificBlue (JS64) all
fromBeckman Coulter; CD56APC-R700 (NCAM16.2), CD38BV510 (HIT2),
and CD27BV605 (L128), all from BD Horizon; and CD45APC-H7 (2D1)
from BD Biosciences, followed by fixation and/or permeabilization and
staining with anti-k fluorescein isothiocyanate and anti-l phycoerythrin
antibodies. The EuroFlow 8-color 2-tube method uses surface-only
staining in 1 tube that consists of individually added antibodies and
a separate tube that uses a 2-step procedure of surface staining
followed by cytoplasmic light chain staining.10 All samples were
acquired by using 1 of 3 standardized FACSCanto 10-color flow
cytometers (BD Biosciences) at MSKCC. To maintain identical
fluorescence and scatter readout over time, daily controls were
used in accordance with guidelines from the US Food and Drug
Administration (FDA) and the National Cancer Institute (NCI).14
MSKCC-derived settings were used for 10-color analysis13
whereas a EuroFlow photomultiplier tube and forward scatter
settings were used for 8-color analysis.15 Analysis of electronic
flow cytometry standard files for both sets of samples was
performed at MSKCC and at Universidad de Salamanca. Expert-
based nonautomated data analysis with Infinicyt software (Cytog-
nos, Salamanca, Spain) was used for both the merged 8-color and
the 10-color flow cytometry standard data files at Universidad de
Salamanca; custom Woodlist software (gift of Dr Brent Wood,
University of Washington, Seattle, WA) was used at MSKCC.
Results
Comparison of methods using MSKCC single 10-color
tube vs EuroFlow two 8-color tubes
The evaluation was performed on FACSCanto 10-color flow cyto-
meters to support both 8- and 10-color analyses. The EuroFlow 8-color
2-tube method was initially reported on a FACSCanto II cytometer;
EuroFlow settings on the FACSCanto 10-color cytometer have not
been validated by the EuroFlow group, but downstream data analysis
was accomplished per the normal EuroFlow protocol. Tomimic standard
laboratory conditions, bone marrow samples were evenly split for the
EuroFlow 8-color 2-tube method and the MSKCC 10-color single-tube
method, and recoveries were calculated.We first assessed total cell and
plasma cell recovery from the 2 panels. Twenty-four samples did not
Table 1. Patients’ characteristics










































CLR, clinical relapse; CR, complete response; F, female; M, male; PD, progressive disease; PR, partial
response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.
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achievemaximal target events (6million cells per tube) and had all events
in the tube collected. Compared with the sum of the cells from the
EuroFlow two 8-color tubes, the MSKCC single 10-color tube had a
slight reduction in total cell numbers with a mean ratio of 0.85 (range,
0.57-1.46; P , .05), which was likely attributable to permeabilization of
the cells (Figure 1A; supplemental Data). Thirty-five (85%) of 41 samples
assessed by the MSKCC 10-color single-tube panel vs 36 (88%) of
41 samples assessed by the EuroFlow 8-color 2-tube method achieved
acquisition of 3 million cells per tube as recommended by the NCI
myeloma working group panel; data regarding achieved numbers by the
MSKCC single 10-color tube and the EuroFlow two 8-color tubes are
provided in the supplemental Data. The proportion of total plasma cells
within the white blood cell gate showed a high degree of concordance
(r25 0.97), as did the percentage of normal plasma cells (r25 0.96) and
abnormal plasma cells (r25 0.97) (Figure 1B-D). These data suggest
only a minor but statistically significant loss of cells; no selective loss of
plasma cells occurred with permeabilization in bone marrow samples.
The overall relative yield and quantitation of abnormal plasma cells were
highly similar between the 2 tests (r2 5 0.97) (Figure 1D-E). Highly
concordant analytical results were obtained with an overall qualitative
concordance of 98% (Figure 1F). A single discrepancy occurred near
the limit of detection for both panels (the EuroFlow two 8-color tubes
were MRD positive and the MSKCC single 10-color tube was MRD
negative), favoring a slightly higher theoretical sensitivity for the EuroFlow
two 8-color tubes, as previously suggested.10
Discussion
We demonstrate that the performance of a single 10-color tube is
comparable to that of the EuroFlow 2-tube approach. The analytical
sensitivity limit of the MSKCC single 10-color tube was recently
evaluated and found to be 6 3 1026 (ie, 6 cells in 1 million) with at
least 3 million cell acquisitions13 compared with the theoretical limit
of detection for the 2-tube 8-color approach of 23 1026 (ie, 2 cells
A
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Y = 0.9950*X + 875651
Total Cell Acquisition
r2=0.6440
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Figure 1. Comparison of MSKCC single 10-color tube and EuroFlow two 8-color tubes. (A) Total cell acquisition, percentage of (B) total plasma cells (PCs),
(C) normal plasma cells, and (D) abnormal plasma cells, along with (E-F) tables containing a summary of the data.
730 ROSHAL et al 9 MAY 2017 x VOLUME 1, NUMBER 12
in 1 million) for the EuroFlow recommended targeted acquisition of
10 million cells.10 Both tests have been validated to detect at least
20 abnormal cells in a sample. The real-world sensitivity of both
tests strongly depends on the quality of the samples. Thus, the
documented sensitivity limit and the published recommendations
regarding MRD test development for both the MSKCC single
10-color tube and the EuroFlow 2-tube approaches are in accord
with FDA-NCI guidelines,14 international consensus recommenda-
tions for myeloma flow cytometry-based MRD quality control,16,17
and the IMWG clinical response criteria for MRD negativity.11
Further efforts to wide adoption of the specific 10-color single-tube test
still remain. For example, although the EuroFlow 8-color 2-tube method
uses automated analysis, which provides a hint to the potential for
hemodilution, is supplemented by expert review, and relies on a data-
base of normal samples,9 there is no such database for the 10-color
single-tube method.10,13 In our study, this potential pitfall did not result
in degradation of test interpretation, but the problem may arise when
the test is transferred to different institutions with various degrees of
expertise. However, in principle there should be no barrier to creating a
database of normal samples for a single institution that uses proprietary
Infinicyt software or for forming a collaborative group that uses
standardized sample processing and acquisition procedures after full
validation of the procedure, as has already been done for the EuroFlow
8-color 2-tube approach.9 Conversely, the analytic approach used in
this study for the MSKCC single 10-color tube does not require
specific proprietary software. We chose to use the Woodlist software
as a visualization tool for the flow cytometry data in this study, but most
flow cytometry visualization software tools could be used with both the
8-color and the 10-color panels. Overall, the MSKCC 10-color single-
tube MRD approach, which is based on a combination of markers
previously proposed by EuroFlow,12 allows laboratories to implement
the method within their existing analytical workflow.
Wide adoption of myelomaMRD testing will require a continuous quality
assurance program that includes standardization of reporting and a
proficiency program to ensure uniform and accurate reporting between
laboratories.16 An external quality assurance (proficiency) program is
currently available for the EuroFlow 8-color 2-tube panel, but it has not
yet been developed for the MSKCC 10-color single-tube approach.
Given very high concordance between the 2 approaches, it is likely that
the same proficiency program would be applicable for both. As with any
other medical test, one may conjecture that 2 separate measurements
of the same sample (ie, EuroFlow 8-color 2-tube method) could provide
a quality check for consistency in flow cytometry MRD measurements
in clinical settings, especially for very low MRD levels. In this study, the
overall results generated by the 2methodswere highly similar (r25 0.97;
Figure 1D-E). Studies that use a larger number of samples with low-level
infiltration by MRD are needed to confirm and expand on our results.
As is true for all flow cytometry tests that rely on surface-antigen
staining, introducing surface-antigen targeting therapies may result in
degradation of test performance unless alternative clones and reagents
are used such as the multiepitope CD38 reagent proposed and
validated by the EuroFlow Consortium for patients treated with anti-
CD38 drugs (eg, daratumumab).10We are in the process of developing
the MSKCC assay for multiple myeloma patients treated with various
monoclonal antibodies. Having the flexibility to make adjustments in
response to the development of new drugs, competing logistic
pressures, various regulatory approvals, drug availability across multiple
countries, and new more informative markers will require standardization
based on rigorous analytical criteria.16 In parallel with the ongoing
development of flow cytometry assays to match the fast pace of FDA
approvals of new drugs that promote rapid and deep responses to
treatment (ie, more patientswill achieve low-levelMRD),18 there is a need
for flow cytometry–based MRD isolation assays to facilitate molecular
characterization of residual cells by next-generation sequencing.
This study was designed to compare MSKCC’s 10-color single-
tube approach with the established 8-color 2-tube panel developed
and extensively validated by the EuroFlow group in a multicenter
setting.10 The EuroFlow group12 recognizes that there might be
alternative approaches that, once they are appropriately designed,
tested, and validated, will contribute to the overall advancement of
science and improved patient care.
The 10-color single-tube approach is streamlined, which may lead
to its wider adoption and acceptance in laboratories where logistic
and/or financial barriers play a major role. At MSKCC, the 10-color
single-tube method reduces the costs of performing the test
(associated with reagents, instrument time, and labor) without losing
analytical performance. In summary, we report high concordance in a
single-center setting between the EuroFlow 8-color 2-tube panel and
the MSKCC 10-color single-tube panel.
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